Genelabs Withdraws Prasterone Application In Europe; U.S. Confirmatory Trial Stays On Schedule
This article was originally published in The Pink Sheet Daily
Executive SummaryThe company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).